[Maxillary osteonecrosis associated with bisphosphonates].

1) Doutor em Clínica Médica pela Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo FMRP-USP. Médico Assistente do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo HC-FMRP – Ribeirão Preto/SP, Brasil. ) Mestrado em Patologia Oral pela Universidade Federal do Rio Grande do Norte. Professor da Disciplina de Cirurgia e Traumatologia Buco-Maxilo-Facial da Universidade Tiradentes UNIT Aracaju/SE, Brasil. 3) Cirurgião-Dentista graduado pela Universidade Tiradentes UNIT Aracaju/SE, Brasil. 4) Residente de Cirurgia e Traumatologia Buco-Maxilo-Facial do Hospital Universitário Oswaldo Cruz, da Universidade de Pernambuco HUOC/UPE Recife/PE, Brasil. Instituição: Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo FMRP-USP; e Faculdade de Odontologia da Universidade Tiradentes UNIT. Correspondência: José Carlos Pereira, Rua Cedro, Clínica Crânio e Face, n. 234 – 49020-315 Aracaju/SE, Brasil. E-mail: wathson@ig.com.br, antunesctbmf@yahoo.com.br Recebido em: 16/06/2009; aceito para publicação em: 09/09/2009; publicado online em: 15/11/2009. Conflito de interesse: nenhum. Fonte de fomento: nenhuma. Artigo de Revisão

[1]  T. Guise,et al.  Osteoporosis Associated with Cancer Therapy , 2008 .

[2]  S. Silverman,et al.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[3]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  I. Reid,et al.  Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? , 2007, Bone.

[5]  N. Yarom,et al.  Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome , 2007, Osteoporosis International.

[6]  K. Antoniadis,et al.  Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. , 2007, American journal of otolaryngology.

[7]  A. Goss,et al.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[8]  L. Mccauley,et al.  Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. , 2007, Journal of periodontology.

[9]  L. Pace,et al.  Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis , 2007, Annals of Hematology.

[10]  S. Fernandez,et al.  Remodeling dynamics in the alveolar process in skeletally mature dogs. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[11]  J. Bilezikian.  Osteonecrosis of the jaw--do bisphosphonates pose a risk? , 2006, The New England journal of medicine.

[12]  E. Terpos,et al.  Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients , 2006, British journal of haematology.

[13]  T. Hansen,et al.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[14]  A. Schwarer,et al.  Bisphosphonate‐associated osteonecrosis of the auditory canal , 2006, British journal of haematology.

[15]  J. Kalmar,et al.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. , 2006, Annals of internal medicine.

[16]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Epstein,et al.  Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. , 2005, Journal of the American Dental Association.

[18]  R. Marx,et al.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[19]  B. Durie,et al.  Osteonecrosis of the jaw and bisphosphonates. , 2005 .

[20]  R. Shaham,et al.  Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. , 2004, The American journal of medicine.

[21]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[22]  C. Migliorati.  Bisphosphanates and oral cavity avascular bone necrosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Devy,et al.  Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.

[26]  J. Devogelaer.  Clinical use of bisphosphonates , 1996, Current opinion in rheumatology.